Stocklytics Platform
Asset logo for symbol ERNA
Eterna Therapeutics
ERNA37
$1.81arrow_drop_up0.55%$0.01
Penny Stock
Asset logo for symbol ERNA
ERNA37

$1.81

arrow_drop_up0.55%

Performance History

Chart placeholder
Key Stats
Open$1.80
Prev. Close$1.80
EPS-4.25
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$9.73M
PE Ratio-
LOWHIGH
Day Range1.76
1.85
52 Week Range0.84
2.91
Ratios
Revenue-
EBITDA Margin %-
EPS-4.25

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Asset logo for symbol LLY
Eli Lilly & Co
LLY74
Price$804.62
Perf. (24h)
arrow_drop_down2.01%-$16.57
Market Cap$724.48B
Asset logo for symbol UNH
UnitedHealth Group
UNH71
Price$569.71
Perf. (24h)
arrow_drop_up1.79%$10.03
Market Cap$527.83B
Asset logo for symbol JNJ
Johnson & Johnson
JNJ62
Price$160.64
Perf. (24h)
arrow_drop_up0.62%$1.00
Market Cap$386.60B
Asset logo for symbol ABBV
AbbVie
ABBV62
Price$185.16
Perf. (24h)
arrow_drop_up1.64%$2.99
Market Cap$326.96B

About Eterna Therapeutics (ERNA)

Eterna Therapeutics Inc., also known by its ticker symbol ERNA, is a biotechnology company that focuses on the development and commercialization of innovative therapies for various diseases. The company is dedicated to advancing the field of precision medicine and personalized therapeutics to improve patient outcomes. With a strong team of scientists and researchers, Eterna Therapeutics Inc. is at the forefront of cutting-edge research and development in the biotechnology industry.
The stock price history of Eterna Therapeutics Inc. (ERNA) reflects the company's growth and potential. Over the years, the stock has shown a steady increase in value, with occasional fluctuations in response to market conditions and industry dynamics. Investors who have been tracking ERNA stock have witnessed its promising performance and have taken positions in anticipation of future growth.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Matthew Angel Ph.D.
Headquarters
Cambridge
Employees
9
Exchange
NASDAQ
add Eterna Therapeutics to watchlist

Keep an eye on Eterna Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Eterna Therapeutics's (ERNA) price per share?
The current price per share for Eterna Therapeutics (ERNA) is $1.81. The stock has seen a price change of $0.01 recently, indicating a 0.56% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Eterna Therapeutics (ERNA)?
For Eterna Therapeutics (ERNA), the 52-week high is $2.91, which is 60.77% from the current price. The 52-week low is $0.84, the current price is 115.48% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Eterna Therapeutics (ERNA) a growth stock?
Eterna Therapeutics (ERNA) has shown an average price growth of 0.41% over the past three years. It has received a score of -3 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Eterna Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Eterna Therapeutics (ERNA) stock price performance year to date (YTD)?
As of the latest data, Eterna Therapeutics (ERNA) has a year-to-date price change of -3.72%. Over the past month, the stock has experienced a price change of 1.69%. Over the last three months, the change has been 1.12%. Over the past six months, the figure is 8.38%.
help
Is Eterna Therapeutics (ERNA) a profitable company?
Eterna Therapeutics (ERNA) has a net income of -$21.67M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -12.31K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$20.67M. Furthermore, the EBITDA is -$21.04M.
help
What is the market capitalization of Eterna Therapeutics (ERNA)?
Eterna Therapeutics (ERNA) has a market capitalization of $9.74M. The average daily trading volume is 16.97K, indicating the stock's liquidity and investor engagement.

News

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
CALENDAR OF EVENTS
HEALTH
PRODUCT / SERVICES ANNOUNCEMENT
5/10/2024

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
DIRECTORS AND OFFICERS
5/8/2024

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
DIRECTORS AND OFFICERS
2/20/2024

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
HEALTH
STOCK MARKET NEWS
1/3/2024

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
DIRECTORS AND OFFICERS
12/20/2023

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
FINANCING AGREEMENTS
12/14/2023

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level